GTS Securities LLC Has $520,000 Stake in Cencora, Inc. (NYSE:COR)

GTS Securities LLC lowered its stake in Cencora, Inc. (NYSE:COR - Free Report) by 94.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,314 shares of the company's stock after selling 36,634 shares during the period. GTS Securities LLC's holdings in Cencora were worth $520,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of COR. Hickory Asset Management Inc. purchased a new position in Cencora in the 4th quarter worth approximately $572,000. Sylvest Advisors LLC bought a new position in shares of Cencora in the 4th quarter valued at about $1,105,000. Vontobel Holding Ltd. lifted its stake in Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock worth $1,403,000 after purchasing an additional 1,995 shares during the last quarter. Milestone Asset Management LLC increased its position in shares of Cencora by 430.2% during the fourth quarter. Milestone Asset Management LLC now owns 5,461 shares of the company's stock worth $1,227,000 after acquiring an additional 4,431 shares during the period. Finally, Portfolio Design Labs LLC increased its holdings in Cencora by 76.9% during the fourth quarter. Portfolio Design Labs LLC now owns 11,032 shares of the company's stock valued at $2,479,000 after buying an additional 4,794 shares during the period. 97.52% of the stock is owned by institutional investors.

Insider Activity

In other news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the sale, the chairman now owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. This trade represents a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the firm's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the transaction, the executive vice president now owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 45,223 shares of company stock valued at $12,369,767 in the last ninety days. 10.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on COR shares. Wells Fargo & Company lifted their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Robert W. Baird upped their price objective on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Evercore ISI increased their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Bank of America increased their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Finally, Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $301.18.

Cencora Stock Up 0.3%

NYSE COR traded up $0.80 during trading on Friday, reaching $291.49. The company's stock had a trading volume of 3,890,003 shares, compared to its average volume of 1,537,835. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The stock has a market capitalization of $56.50 billion, a PE ratio of 41.46, a PEG ratio of 1.31 and a beta of 0.60. The business has a 50-day moving average price of $284.83 and a 200-day moving average price of $258.61. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the previous year, the firm posted $3.80 earnings per share. Cencora's revenue was up 10.3% compared to the same quarter last year. On average, research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Shareholders of record on Friday, May 16th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.75%. Cencora's dividend payout ratio is currently 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.